Acumen reports Q2 2025 net loss $41M, cash $166.2M; Phase 2 Alzheimer's topline expected late 2026

Acumen Pharmaceuticals, Inc.

2025-Q2 EPS reported -$1.15 vs consensus -$0.55 ▼ miss (-109.5%)

Cash, equivalents, and marketable securities totaled $166.2M as of June 30, 2025, expected to fund operations into early 2027.
Net loss for Q2 2025 was $41.0M compared to $20.5M in Q2 2024, driven by higher R&D expenses.
Topline results from Phase 2 ALTITUDE-AD trial of sabirnetug for early Alzheimer's expected in late 2026.
Announced collaboration with JCR Pharmaceuticals for Enhanced Brain Delivery therapy; non-clinical data expected early 2026.
At AAIC 2025, presented data showing sabirnetug has 8,750-fold selectivity for toxic amyloid beta oligomers over monomers.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.